5H

Shanghai Haohai Biological Technology Co LtdFRA Shanghai Haohai Stock Report

Last reporting period 30 Jun, 2024

Updated 22 Oct, 2024

Last price

Market cap $B

1.819

Small

Exchange

XFRA - Deutsche Boerse AG

5HB.F Stock Analysis

5H

Uncovered

Shanghai Haohai Biological Technology Co Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

94/100

Moderate score

Market cap $B

1.819

Dividend yield

1.49 %

Shares outstanding

169.58 B

Shanghai Haohai Biological Technology Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Shanghai, Shanghai and currently employs 1,892 full-time employees. The company went IPO on 2015-04-30. Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The firm mainly operates businesses in Mainland China.

View Section: Eyestock Rating